Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates.

Carterra’s high-throughput LSA® platform for monoclonal antibody (mAb) screening and characterization combines patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry leading Kinetic and Epitope analysis and visualization software. The newly launched LSA-XT platform with enhanced optics enables additional applications in biotherapeutic discovery and characterization such as DELs, PROTACs, kinases, protein:protein inhibitors and more. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms.